Back to List View Graph View

Butyrylcholinesterase (BCHE)

Butyrylcholinesterase (BChE; also known as pseudocholinesterase, plasma cholinesterase, or non-specific cholinesterase) is a serine hydrolase enzyme encoded by the BCHE gene in humans.

Where the papers sit

16 papers from the last 6 months study Butyrylcholinesterase (BCHE) directly · updated from PubMed 9 Nov 2026

Study type 0 clinical trials · 5 human data · 11 preclinical

Themes 3 themes

  • Alzheimer Cholinesterase Drug Discovery

    Alzheimer drug discovery is increasingly combining cholinesterase inhibition with hybrid scaffolds, neuroprotective activity and computational prioritization. Molecular docking and dynamics are repeatedly used to explain binding to AChE or BChE, while ADMET profiling helps rank compounds for testing. Reported candidates include indolinone, carbamate, coumarin, quinoline and flavonoid-derived molecules, often with nanomolar or multitarget activity. Experimental confirmation remains uneven, and translation beyond enzyme assays is still open.

    10 papers · 62.5%

  • Multitarget Neurodegeneration Therapies

    Enzyme-directed neurodegeneration research is moving from selective MAO-B inhibition toward multitarget ligands that combine BChE and MAO-B activity. Piperidine chalcones are being evaluated for anti-Parkinson potential, while urea and thiourea scaffolds target Alzheimer-related cholinesterase pathways. Microglia-associated neuroinflammation and neuroprotection recur as biological aims. Evidence remains predominantly biochemical and preclinical, leaving in vivo efficacy and selectivity open.

    3 papers · 18.8%

  • Dual Cholinesterase Inhibitor Design

    Synthetic Alzheimer drug design is favoring dual cholinesterase inhibitors built from benzimidazolone, thiohydantoin and oxadiazole scaffolds. Several compounds also inhibit COX or carbonic anhydrase, extending the strategy toward multi-target control of neurodegenerative and inflammatory pathways. Structural characterization and enzyme-kinetic testing recur across the work. The studies establish candidate activity rather than clinical benefit, with cellular and in vivo validation still limited.

    3 papers · 18.8%

Papers

The 16 papers from the last 6 months that study Butyrylcholinesterase (BCHE) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Alzheimer Cholinesterase Drug Discovery (10)
  1. New hybrid molecules with 2,3,4,9-tetrahydro-1H-carbazol-1,3,4-oxadiazole-N-phenylacetamide framework as potent cholinesterase inhibitors. Future medicinal chemistry · 22 Oct 2026 PMID 42904391
  2. Virtual screening, structural optimization, computational studies, and biological evaluation of quinoline derivatives as selective butyrylcholinesterase inhibitors. Bioorganic chemistry · 6 Oct 2026 PMID 42837740
  3. Design, synthesis, biological evaluation, and in silico analysis of novel coumarin carboxamides as acetylcholinesterase and butyrylcholinesterase inhibitors and anticancer agents. Journal of computer-aided molecular design · 21 Jul 2026 PMID 42481895
  4. Rational design and synthesis of dispiroindene-pyrrolidinedione scaffolds as multi-target directed ligands: potent AChE inhibitors with antioxidant activity and favorable biocompatibility in SH-SY5Y cells. Bioorganic chemistry · 16 Jul 2026 PMID 42462519
  5. Eugenol-derived carbamates as sub-nanomolar dual cholinesterase inhibitors with neuroprotective activity against Alzheimer's disease: Structure-activity relationships and molecular dynamics insights. Bioorganic chemistry · 13 Jul 2026 PMID 42442298
  6. Novel 2-indolinone benzylpiperidine- thiosemicarbazone hybrids as cholinesterase inhibitors: Design, synthesis and biological evaluation. Bioorganic chemistry · 29 Jun 2026 PMID 42372459
  7. Discovery of New Butyrylcholinesterase Inhibitors and Evaluation of Their Biological Activity against Alzheimer's Disease. ACS chemical neuroscience · 23 Jun 2026 PMID 42335451
  8. β-Maltose-conjugated acetophenone thiosemicarbazones as multitarget inhibitors of diabetes- and Alzheimer's disease-related enzymes: Design, synthesis, and mechanistic evaluation. Bioorganic chemistry · 25 May 2026 PMID 42184581
  9. Promising Flavonoid-Fused Aminoquinolines as Synthetic Alzheimer's Disease Models: Design, Synthesis, Anticholinesterase Activity, ADMET and Molecular Docking. Chembiochem : a European journal of chemical biology · 25 May 2026 PMID 42179001
  10. Studies of design, synthesis and biological properties, ADMET profiling, molecular docking, network pharmacology and molecular dynamics simulation of novel chalcone derivatives containing benzoyl-piperazin. Bioorganic chemistry · 21 May 2026 PMID 42166963
Multitarget Neurodegeneration Therapies (3)
  1. Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents. Drug development research · 6 Jul 2026 PMID 42403010
  2. Leveraging multitargeting BChE-MAO B inhibitors against microglia-related neuroinflammation: in vitro biological evaluation, structure-activity relationships, drug-like properties, and X-ray crystal complexes. European journal of medicinal chemistry · 4 Jun 2026 PMID 42241774
  3. Identification of a nanomolar, selective MAO-B inhibitor from piperidine-based chalcones with anti-Parkinson potential. Bioorganic chemistry · 26 May 2026 PMID 42190536
Dual Cholinesterase Inhibitor Design (3)
  1. Design, synthesis and multitarget evaluation of cyclopropyl-appended thiohydantoin derivatives as dual cholinesterase and COX inhibitors with antioxidant activity: a combined experimental and computational study. Journal of computer-aided molecular design · 11 Sept 2026 PMID 42726329
  2. Sulfonamide-Based 2-Amino-1,3,4-Oxadiazole Derivatives as Dual Cholinesterase and Carbonic Anhydrase Inhibitors: Design, Synthesis, Kinetic Characterization, Molecular Modeling, and ADMET Evaluation. Drug development research · 25 Aug 2026 PMID 42638586
  3. Design, Synthesis, and Biological Evaluation of Benzimidazol-2-One Hybrids as Potential Anti-Alzheimer's Disease Agents. Drug development research · 20 Aug 2026 PMID 42623026

By study type

Human data, design not indexed (5)
  1. Design, synthesis and multitarget evaluation of cyclopropyl-appended thiohydantoin derivatives as dual cholinesterase and COX inhibitors with antioxidant activity: a combined experimental and computational study. Journal of computer-aided molecular design · 11 Sept 2026 PMID 42726329
  2. Novel 2-indolinone benzylpiperidine- thiosemicarbazone hybrids as cholinesterase inhibitors: Design, synthesis and biological evaluation. Bioorganic chemistry · 29 Jun 2026 PMID 42372459
  3. Leveraging multitargeting BChE-MAO B inhibitors against microglia-related neuroinflammation: in vitro biological evaluation, structure-activity relationships, drug-like properties, and X-ray crystal complexes. European journal of medicinal chemistry · 4 Jun 2026 PMID 42241774
  4. β-Maltose-conjugated acetophenone thiosemicarbazones as multitarget inhibitors of diabetes- and Alzheimer's disease-related enzymes: Design, synthesis, and mechanistic evaluation. Bioorganic chemistry · 25 May 2026 PMID 42184581
  5. Promising Flavonoid-Fused Aminoquinolines as Synthetic Alzheimer's Disease Models: Design, Synthesis, Anticholinesterase Activity, ADMET and Molecular Docking. Chembiochem : a European journal of chemical biology · 25 May 2026 PMID 42179001
Preclinical: animal, cell and lab studies (11)
  1. New hybrid molecules with 2,3,4,9-tetrahydro-1H-carbazol-1,3,4-oxadiazole-N-phenylacetamide framework as potent cholinesterase inhibitors. Future medicinal chemistry · 22 Oct 2026 PMID 42904391
  2. Virtual screening, structural optimization, computational studies, and biological evaluation of quinoline derivatives as selective butyrylcholinesterase inhibitors. Bioorganic chemistry · 6 Oct 2026 PMID 42837740
  3. Sulfonamide-Based 2-Amino-1,3,4-Oxadiazole Derivatives as Dual Cholinesterase and Carbonic Anhydrase Inhibitors: Design, Synthesis, Kinetic Characterization, Molecular Modeling, and ADMET Evaluation. Drug development research · 25 Aug 2026 PMID 42638586
  4. Design, Synthesis, and Biological Evaluation of Benzimidazol-2-One Hybrids as Potential Anti-Alzheimer's Disease Agents. Drug development research · 20 Aug 2026 PMID 42623026
  5. Design, synthesis, biological evaluation, and in silico analysis of novel coumarin carboxamides as acetylcholinesterase and butyrylcholinesterase inhibitors and anticancer agents. Journal of computer-aided molecular design · 21 Jul 2026 PMID 42481895
  6. Rational design and synthesis of dispiroindene-pyrrolidinedione scaffolds as multi-target directed ligands: potent AChE inhibitors with antioxidant activity and favorable biocompatibility in SH-SY5Y cells. Bioorganic chemistry · 16 Jul 2026 PMID 42462519
  7. Eugenol-derived carbamates as sub-nanomolar dual cholinesterase inhibitors with neuroprotective activity against Alzheimer's disease: Structure-activity relationships and molecular dynamics insights. Bioorganic chemistry · 13 Jul 2026 PMID 42442298
  8. Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents. Drug development research · 6 Jul 2026 PMID 42403010
  9. Discovery of New Butyrylcholinesterase Inhibitors and Evaluation of Their Biological Activity against Alzheimer's Disease. ACS chemical neuroscience · 23 Jun 2026 PMID 42335451
  10. Identification of a nanomolar, selective MAO-B inhibitor from piperidine-based chalcones with anti-Parkinson potential. Bioorganic chemistry · 26 May 2026 PMID 42190536
  11. Studies of design, synthesis and biological properties, ADMET profiling, molecular docking, network pharmacology and molecular dynamics simulation of novel chalcone derivatives containing benzoyl-piperazin. Bioorganic chemistry · 21 May 2026 PMID 42166963